Shortage reports
Actual shortage:
257 (7%)
Anticipated shortage:
3 (0%)
Avoided shortage:
11 (0%)
Resolved:
3300 (92%)
3571
Discontinuation Reports
To be discontinued:
24 (7%)
Discontinued:
342 (93%)
Reversed:
0 (0%)
366
143 (4%)
32 (11%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-LEVETIRACETAM | 500MG | TABLET | Resolved | 2023-09-07 | 2023-10-27 | 203840 |
| APO-LEVETIRACETAM | 250MG | TABLET | Resolved | 2019-03-20 | 2019-04-26 | 79045 |
| APO-LEVETIRACETAM | 250MG | TABLET | Resolved | 2018-10-19 | 2019-01-10 | 64938 |
| APO-LEVETIRACETAM | 750MG | TABLET | Resolved | 2023-11-17 | 2023-12-15 | 210656 |
| APO-LEVETIRACETAM | 250MG | TABLET | Resolved | 2023-04-14 | 2023-06-23 | 189641 |
| APO-LEVETIRACETAM | 500MG | TABLET | Resolved | 2021-08-27 | 2021-10-01 | 144659 |
| APO-LEVETIRACETAM | 750MG | TABLET | Resolved | 2023-09-15 | 2023-10-27 | 204405 |
| APO-LEVETIRACETAM | 750MG | TABLET | Resolved | 2022-11-20 | 2022-12-23 | 175321 |
| APO-LEVETIRACETAM | 250MG | TABLET | Resolved | 2022-07-15 | 2022-08-24 | 164710 |
| APO-LEVETIRACETAM | 500MG | TABLET | Resolved | 2017-07-26 | 2018-03-15 | 17251 |
| APO-LEVETIRACETAM | 750MG | TABLET | Resolved | 2024-02-02 | 2024-03-15 | 218370 |
| APO-LEVETIRACETAM | 750MG | TABLET | Resolved | 2017-10-03 | 2018-03-15 | 24262 |
| APO-LEVETIRACETAM | 500MG | TABLET | Resolved | 2022-06-27 | 2022-08-24 | 163448 |
| APO-LEVOBUNOLOL OPHTHALMIC SOLUTION USP 0.25% | 0.25% | LIQUID | Actual shortage | 2017-08-13 | 2017-10-05 | 19096 |
| APO-LEVOBUNOLOL OPHTHALMIC SOLUTION USP 0.5% | 0.5% | LIQUID | Actual shortage | 2017-08-13 | 2017-10-05 | 19093 |
| APO-LEVOCARB - TAB 25MG/250MG | 25MG 250MG | TABLET | Resolved | 2019-02-06 | 2019-03-01 | 74911 |
| APO-LEVOCARB - TAB 25MG/250MG | 25MG 250MG | TABLET | Resolved | 2017-08-23 | 2017-11-09 | 20108 |
| APO-LEVOCARB - TAB 25MG/250MG | 25MG 250MG | TABLET | Resolved | 2021-03-26 | 2021-05-10 | 136403 |
| APO-LEVOCARB - TAB 25MG/250MG | 25MG 250MG | TABLET | Resolved | 2017-10-03 | 2017-11-09 | 24265 |
| APO-LEVOCARB - TAB 25MG/250MG | 25MG 250MG | TABLET | Resolved | 2020-12-28 | 2021-02-22 | 130710 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BROMAZEPAM - TAB 1.5MG | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM - TAB 3MG | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM - TAB 6MG | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |